SEC Form 4 · accession 0001645627-18-000054
ENDONOVO THERAPEUTICS, INC. · ENDV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Scott Mann
Officer — President · 10% Owner
Period of report
Aug 30, 2018
Accepted (ET)
Sep 6, 2018 · 1:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001528172
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 30, 2018 | P | 2,000 | $0.0433 | A | 25,829,698 | D | |
| Common Stock | Aug 30, 2018 | P | 1,000 | $0.043 | A | 25,830,698 | D | |
| Common Stock | Aug 30, 2018 | P | 2,000 | $0.0415 | A | 25,832,698 | D | |
| Common Stock | Aug 30, 2018 | P | 1,000 | $0.0425 | A | 25,833,698 | D | |
| Common Stock | Aug 30, 2018 | P | 1,000 | $0.0437 | A | 25,834,698 | D | |
| Common Stock | Aug 31, 2018 | P | 2,000 | $0.0493 | A | 25,836,698 | D | |
| Common Stock | Aug 31, 2018 | P | 2,000 | $0.0528 | A | 25,838,698 | D | |
| Common Stock | Aug 31, 2018 | P | 1,000 | $0.0523 | A | 25,839,698 | D | |
| Common Stock | Aug 31, 2018 | P | 1,000 | $0.0529 | A | 25,840,698 | D | |
| Common Stock | Aug 31, 2018 | P | 2,000 | $0.0529 | A | 25,842,698 | D | |
| Common Stock | Aug 31, 2018 | P | 1,000 | $0.054 | A | 25,843,698 | D | |
| Common Stock | Aug 31, 2018 | P | 1,000 | $0.0543 | A | 25,844,698 | D | |
| Common Stock | Aug 31, 2018 | P | 500 | $0.0547 | A | 25,845,198 | D | |
| Common Stock | Sep 4, 2018 | P | 1,000 | $0.0541 | A | 25,846,198 | D | |
| Common Stock | Sep 4, 2018 | P | 1,000 | $0.0534 | A | 25,847,198 | D | |
| Common Stock | Sep 4, 2018 | P | 1,000 | $0.0535 | A | 25,848,198 | D | |
| Common Stock | Sep 4, 2018 | P | 1,000 | $0.0486 | A | 25,849,198 | D | |
| Common Stock | Sep 4, 2018 | P | 2,000 | $0.0487 | A | 25,851,198 | D | |
| Common Stock | Sep 4, 2018 | P | 2,000 | $0.0486 | A | 25,853,198 | D | |
| Common Stock | Sep 4, 2018 | P | 2,000 | $0.0487 | A | 25,855,198 | D |
Table II — derivative securities
No Table II lines on this filing.